Aneurysmal Subarachnoid HemorrhageNCT07652749
Stellate Ganglion Block and Prognosis of Neurological Function After Subarachnoid Hemorrhage
A study testing Intervention group in people with Aneurysmal Subarachnoid Hemorrhage and Stellate Ganglion Block, run by Beijing Tiantan Hospital at 1 site in China.
Trial summary
The incidence of cerebral vasospasm after aneurysm subarachnoid hemorrhage (aSAH) is as high as 70%; cerebral vasospasm（CVS） is closely related to delayed cerebral ischemia （DCI）, which is one of the important reasons for poor outcomes in patients with aSAH. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Aneurysmal Subarachnoid Hemorrhage, Stellate Ganglion Block, Neurological Prognosis
- What is being tested?
- Intervention group
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 560 participants
- Where
- 1 siteChina
- Study dates
- 15 Jun 2026to 31 Mar 2029
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age range: 18-65 years old;
- Within 72 hours after onset of aSAH,and planning surgical treatment(aneurysm embolizing or clipping);
- Preoperative Hunt-Hess grade 2-3
- Sign informed consent.
Who cannot join
- ASA > grade IV;
- Patients with posterior circulation aneurysm;
- Patients with severe systemic hemorrhagic diseases;
- Patients with trauma and local infection in the nerve block area;
- Local anatomic structure changes (neck structure changes caused by radiotherapy, chemotherapy and surgery);
- Allergy to known local anesthetics;
- Pregnant and lactating women.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100070
Ruquan Han, M.D., Ph.D, 8610-59976660, ruquan.han@gmail.com
Ruquan Han, M.D., Ph.D
About this study
Official title: Effect of Stellate Ganglion Block on the Prognosis of Neurological Function After Subarachnoid Hemorrhage
The incidence of cerebral vasospasm after aneurysm subarachnoid hemorrhage (aSAH) is as high as 70%; cerebral vasospasm（CVS） is closely related to delayed cerebral ischemia （DCI）, which is one of the important reasons for poor outcomes in patients with aSAH.
In recent years, it has been reported that stellate ganglion block(SGB) can effectively alleviate cerebral vasospasm(CVS), reduce cerebral blood flow velocity and increase cerebral perfusion in patients with aneurysm subarachnoid hemorrhage(aSAH)。However, whether the alleviation of CVS after SGB is beneficial to the long-term neurological prognosis has not been confirmed Therefore, a prospective randomized controlled study is needed to further explore the role of SGB block in improving the outcomes of patients with aSAH.
- Being tested
- Intervention group
- Medical subject headings
- Subarachnoid Hemorrhage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intervention groupProcedure or surgery
Also called Stellate ganglion block
Prior to the initiation of surgery, a single ultrasound-guided stellate ganglion block was performed on the ipsilateral side of the lesion.The dose and concentration of local anesthesia: 0.5% ropivacaine 5-10ml. Criteria for successful block: the patient developed Horner's syndrome, characterized by miosis, ptosis, eyeball caved in, nasal congestion, conjunctival congestion, reddish face and no sweat on the face
| Study group | Role | What they receive |
|---|---|---|
| Intervention group | Experimental | In addition to routine anesthesia management and surgical operations, an ultrasound-guided stellate ganglion block was performed once prior to the initiation of surgery, and then receive standard care after operation. Related statistical indicators were collected prospectively. Receives: Procedure: Intervention group |
| Blank control group | No intervention | In this study, a blank control was used. Routine anesthesia management and surgical operation were used without any special interventions, and then receive standard care after operation. Only relevant statistical indicators were collected prospectively. |
What is being measured
The primary outcome is the main question the study is designed to answer.
The modified Rankin Scale (mRS) scores at 90 days
The modified Rankin Scale (mRS) is used to evaluate the primary outcome. The scale of mRS is 0 to 6. The best neurological outcome is the mRS with 0, indicating no any symptom left. mRS of 6 is the worst, indicating death. mRS will be evaluated by outcomes assessor who is blinded to the grouping.
Measured: 90 days postoperatively
Secondary outcomes (4)
The incidence of delayed cerebral ischemia (DCI) during hospitalization
Measured: At discharge, an average of 2 weeks
All cause mortality during 90 days after onset
Measured: 90 days postoperatively
Length of stay in the intensive care unit and hosipital
Measured: At discharge, an average of two weeks
Adverse events during hospitalization
Myocardial infarction, cardiac arrest, pulmonary embolism, infection, SGB related complications, etc
Measured: At discharge, an average of 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jun 2026
- Study start15 Jun 2026 (estimated)
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Mar 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Aneurysmal Subarachnoid HemorrhageStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 560 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beijing Tiantan Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ruquan Han, Beijing Tiantan Hospital
- Investigators
- Ruquan Han, M.D., Ph.D, Principal investigator, Beijing Tiantan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07652749
- Sponsor's protocol ID
- Z191100006619069
- Status last verified
- Jun 2026
- First submitted
- 2 Mar 2021
- Last updated
- 17 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No